Ansa Biotechnologies Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
59
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$56.9M
- Investors
-
31
Ansa Biotechnologies General Information
Description
Developer of a novel DNA synthesis platform designed to enable reliable production of complex genetic sequences for biological research and biotechnology applications. The company's products are manufactured using a proprietary enzymatic DNA synthesis process based on TdT-dNTP conjugates, allowing direct synthesis of complex DNA fragments and sequence-perfect clonal DNA up to 50 kb with reduced reliance on DNA assembly, enabling researchers to access difficult-to-synthesize genetic constructs for applications in synthetic biology, gene therapy, vaccine research, and other life-science fields.
Contact Information
Website
www.ansabio.comCorporate Office
- 1198 65th Street
- Suite 250
- Emeryville, CA 94608
- United States
Corporate Office
- 1198 65th Street
- Suite 250
- Emeryville, CA 94608
- United States
Ansa Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series B) | 10-Oct-2025 | $56.9M | Completed | Generating Revenue | ||
| 7. Early Stage VC (Series A) | 11-Apr-2022 | Completed | Generating Revenue | |||
| 6. Early Stage VC | 15-Oct-2021 | Completed | Generating Revenue | |||
| 5. Grant | 01-Jan-2021 | Completed | Generating Revenue | |||
| 4. Seed Round | 09-Jul-2020 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 01-Jan-2020 | Completed | Generating Revenue | |||
| 2. Grant | 19-Jun-2019 | $225K | Completed | Generating Revenue | ||
| 1. University Spin-Out | 01-May-2018 | Completed | Startup |
Ansa Biotechnologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-Ext | ||||||||
| Series B-1 Plus | ||||||||
| Series B Plus | 70,227,521 | $0.000100 | $0.35 | $0.35 | 1x | $0.35 | 9.03% | |
| Series A Plus | 2,046,754 | $0.000100 | $3.62 | $3.62 | 1x | $3.62 | 0.26% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Ansa Biotechnologies Comparisons
Industry
Financing
Details
Ansa Biotechnologies Competitors (6)
One of Ansa Biotechnologies’s 6 competitors is Integrated DNA Technologies, a Formerly PE-Backed company based in Coralville, IA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Integrated DNA Technologies | Formerly PE-Backed | Coralville, IA | ||||
| DNA Script | Venture Capital-Backed | Paris, France | ||||
| Twist Bioscience | Formerly VC-backed | South San Francisco, CA | ||||
| Genewiz | Formerly VC-backed | South Plainfield, NJ | ||||
| GenScript | Formerly VC-backed | Nanjing, China |
Ansa Biotechnologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ansa Biotechnologies Patents
Ansa Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026187839-A2 | Error correction of synthetic polynucleotides using branch migration | Pending | 03-Mar-2025 | ||
| WO-2026187839-A3 | Error correction of synthetic polynucleotides using branch migration | Pending | 03-Mar-2025 | ||
| WO-2026035983-A1 | Modified nucleotides and nucleotide conjugates for polynucleotide synthesis | Pending | 07-Aug-2024 | ||
| WO-2025155732-A1 | Improved methods and compositions for cloning de novo-synthesized polynucleotides | Pending | 16-Jan-2024 | ||
| EP-4731762-A2 | De novo stepwise template-independent synthesis of long polynucleotides | Pending | 21-Jun-2023 | C07H1/00 |
Ansa Biotechnologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ansa Biotechnologies Investors (31)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alternative Investment Management | Family Office | Minority | ||
| Black Opal Ventures | Venture Capital | Minority | ||
| Cerberus Ventures | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| Dauntless Ventures | Venture Capital | Minority |
Ansa Biotechnologies FAQs
-
When was Ansa Biotechnologies founded?
Ansa Biotechnologies was founded in 2018.
-
Where is Ansa Biotechnologies headquartered?
Ansa Biotechnologies is headquartered in Emeryville, CA.
-
What is the size of Ansa Biotechnologies?
Ansa Biotechnologies has 59 total employees.
-
What industry is Ansa Biotechnologies in?
Ansa Biotechnologies’s primary industry is Biotechnology.
-
Is Ansa Biotechnologies a private or public company?
Ansa Biotechnologies is a Private company.
-
What is the current valuation of Ansa Biotechnologies?
The current valuation of Ansa Biotechnologies is .
-
What is Ansa Biotechnologies’s current revenue?
The current revenue for Ansa Biotechnologies is .
-
How much funding has Ansa Biotechnologies raised over time?
Ansa Biotechnologies has raised $140M.
-
Who are Ansa Biotechnologies’s investors?
Alternative Investment Management, Black Opal Ventures, Cerberus Ventures, , and Dauntless Ventures are 5 of 31 investors who have invested in Ansa Biotechnologies.
-
Who are Ansa Biotechnologies’s competitors?
Integrated DNA Technologies, DNA Script, Twist Bioscience, Genewiz, and GenScript are some of the 6 competitors of Ansa Biotechnologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
